BridgeBio Pharma, Inc.
BBIO
Rank in Stocks
#1618
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Share Price
$68.10
Market Cap
$13.31B
Change (1 day)
2.57%
Change (1 year)
24.00%
Country
US
Trade BridgeBio Pharma, Inc. (BBIO)
Category
Healthcare
P/E ratio for BridgeBio Pharma, Inc. (BBIO)
P/E ratio as of October 2026 TTM: -18.14
According to BridgeBio Pharma, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -18.14. At the end of 2023 the company had a P/E ratio of -10.22.
P/E ratio history for BridgeBio Pharma, Inc. from 2017 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -18.14 | 90.34% |
| 2024 | -9.53 | -6.73% |
| 2023 | -10.22 | 337.51% |
| 2022 | -2.34 | -45.44% |
| 2021 | -4.28 | -77.11% |
| 2020 | -18.70 | 32.20% |
| 2019 | -14.14 | -27.30% |
| 2018 | -19.45 | -76.62% |
| 2017 | -83.22 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -258.67% |
US
|
|
| -28.36 | 56.33% |
US
|
|
| -24.57 | 35.43% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -267.20% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.